MULTI-LAYER AMNIOTIC TISSUE GRAFTS AND USES THEREOF
The present invention provides a tissue graft product comprising a plurality of laminated layers of extracellular matrix. wherein the extracellular matrix is derived from an amniotic membrane, and wherein the stromal side of an extracellular matrix layer is presented on both the upper and lower surfaces of the tissue graft product. Methods of making and using the tissue graft product also are provided.
1 . A tissue graft product comprising a plurality of layers of extracellular matrix laminated together, wherein the extracellular matrix is derived from an amniotic membrane, and wherein the stromal side of an extracellular matrix layer is presented on both the upper and lower surfaces of the tissue graft product.
2 . The tissue graft product of claim 1 , wherein the product comprises three or more layers of extracellular matrix.
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . The tissue graft product of claim 1 , wherein the tissue graft product is dehydrated.
10 . The tissue graft product of claim 1 , wherein the product comprises less than about 20%, less than about 15%, or less than about 10% water by dry weight.
11 . (canceled)
12 . (canceled)
13 . The tissue graft product of claim 1 , wherein the product comprises about 40% to about 70% total collagen by dry weight, about 45% to about 60% total collagen by weight, or about 50% to about 55% total collagen by dry weight.
14 . (canceled)
15 . (canceled)
16 . The tissue graft product of claim 13 , wherein the collagen is primarily collagen type I and collagen type III.
17 . The tissue graft product of claim 1 , wherein the product comprises about 8% to about 24% elastin by dry weight, about 12% to about 20% elastin by dry weight, or about 15% to about 20% elastin by dry weight.
18 . (canceled)
19 . (canceled)
20 . The tissue graft product of claim 1 , wherein the product comprises less than about 1% glycosaminoglycan by dry weight, or less than about 0.5% glycosaminoglycan by dry weight.
21 . (canceled)
22 . The tissue graft product of claim 1 , wherein the product comprises less than about 1% fibronectin by dry weight, or less than about 0.5% fibronectin by dry weight.
23 . (canceled)
24 . The tissue graft product of claim 1 , wherein the product comprises less than about 1% laminin by dry weight, or less than about 0.5% laminin by dry weight.
25 . (canceled)
26 . The tissue graft product of claim 1 , wherein the amniotic membrane is a human amniotic membrane.
27 . The tissue graft product of claim 26 , wherein the amniotic membrane is derived from a full-term pregnancy.
28 . An ocular tissue graft comprising the tissue graft product of claim 1 .
29 . The ocular tissue graft of claim 28 , wherein the ocular tissue graft is approximately circular.
30 . The ocular tissue graft of claim 28 , wherein the ocular tissue graft comprises a curved portion in the shape of a portion of a sphere.
31 . (canceled)
32 . A method of treating a disease or injury of the eye in a subject, the method comprising the step of contacting the eye of the subject with: (a) a tissue graft product comprising a plurality of layers of extracellular matrix laminated together, wherein the extracellular matrix is derived from an amniotic membrane, and wherein the stromal side of an extracellular matrix layer is presented on both the upper and lower surfaces of the tissue graft product: or (ii) an ocular tissue graft comprising a plurality of layers of extracellular matrix laminated together, wherein the extracellular matrix is derived from an amniotic membrane, and wherein the stromal side of an extracellular matrix layer is presented on both the upper and lower surfaces of the tissue graft product, wherein the ocular tissue graft comprises a curved portion in the shape of a portion of a sphere, so as thereby to treat the subject.
33 . The method of claim 32 , wherein the disease or injury of the eye in the subject comprises: (i) an abrasion: (ii) a chemical exposure: (iii) a cut or laceration; a disease or injury of the cornea: (iii) repair of a damaged tissue: (iv) a reduction in scar tissue; (v) a reduction in scar tissue formation relative to an untreated eye: (vi) increasing epithelial cell migration relative to an untreated eye: (vii) increasing epithelial cell adhesion relative to an untreated eye: (viii) increasing epithelial cell proliferation relative to an untreated eye: or (ix) increasing epithelial cell coverage relative to an untreated eye.
34 - 42 . (canceled)
43 . The method of claim 32 , wherein the subject is a mammal.
44 . The method of claim 43 , wherein the subject is a human.